What We Know About the University of Chicago Diabetes Trial

All 12 participants in a University of Chicago clinical trial that paired islet cell transplants with a new anti-rejection drug have potentially been cured of Type 1 diabetes, according to a report by NBC Nightly News correspondent Anne Thompson that aired Oct. 4, 2026. The segment, available on NBC News, described the result as the outcome of a trial testing whether transplanted cells can restore insulin production without the immune system attacking the new tissue.

What did the University of Chicago trial involve?

According to NBC News, the trial enrolled 12 people with Type 1 diabetes. Each received a transplant of islet cells — the insulin-producing cells normally found in the pancreas — along with a new drug designed to stop the body from rejecting the transplanted tissue. The network's report characterized the outcome as having "potentially cured" all 12 participants, though the segment did not specify a trial phase, enrollment criteria, or how long participants have been followed since receiving the transplant.

How does the islet cell procedure work?

Islet cells are clusters of cells inside the pancreas that produce insulin, the hormone the body needs to move sugar out of the bloodstream and into cells for energy. In Type 1 diabetes, the immune system destroys these cells, leaving patients dependent on injected or pumped insulin for life. Transplanting donor islet cells is intended to give the body a new, functioning source of insulin production, according to the mechanism described in the NBC News report.

What role does the new anti-rejection drug play?

The central challenge with any cell or organ transplant is that the recipient's immune system will often attack and destroy the new tissue, treating it as a foreign invader. NBC News reported that the University of Chicago trial combined the islet cell transplant with a new drug specifically intended to prevent that rejection response. The network's report did not name the drug or detail its mechanism, dosing, or side-effect profile.

How reliable is the "cured" claim?

NBC News' on-air description called the result a potential cure for all 12 trial participants, but the network's publicly available segment did not include independent peer-reviewed data, a published study, specific insulin-independence timelines for each patient, or comment from the research team leading the work. Those details — typically the standard against which clinical breakthroughs are measured — were not part of the material NBC News made available in its Oct. 4 broadcast. The claim as reported should be read as an early trial result relayed by NBC News, not as a finding confirmed through a published, peer-reviewed study.

"A groundbreaking clinical trial at the University of Chicago has potentially cured all 12 participants of Type 1 diabetes," NBC News reported Oct. 4, 2026.

What should patients and researchers watch for next?

Because the NBC News report is, so far, the only publicly available account of this specific trial result, several questions remain open heading into any further disclosure from the University of Chicago or the research team involved.

• Whether the trial results are submitted to a peer-reviewed medical journal, which would allow independent scientists to evaluate the data
• How long the 12 participants are followed to confirm insulin independence holds over months or years, not just at an early checkpoint
• Whether the new anti-rejection drug is identified publicly and reviewed by regulators such as the Food and Drug Administration
• Whether the approach is tested in a larger group of patients beyond the initial 12
• Whether University of Chicago researchers or hospital officials issue a statement or press release with additional trial details

Where can viewers watch the full NBC report?

The full 2-minute, 14-second segment, reported by Anne Thompson, aired on NBC Nightly News on Oct. 4, 2026, and is posted on NBC News' website. As of this report, it remains the only publicly cited account of the University of Chicago trial's outcome. Readers looking for primary clinical data, the name of the anti-rejection drug, or peer-reviewed confirmation will need to wait for the University of Chicago or the trial's researchers to release that material directly.